Article | July 30, 2019

Investigational New Drug Applications: Four Common Mistakes

Help-Laptop-Over-Head-Frustrated-iStock-658516626

Before starting Phase I trials, an Investigational New Drug (IND) application must be approved by the FDA. This critical early step in clinical trial development grants an exemption to laws prohibiting the transportation of drugs across state lines prior to market approval.

The three major required areas of information in an IND include:

  • Animal pharmacology and toxicology studies
  • Manufacturing information
  • Clinical protocols and investigator information

Of course, putting this all together in a single, cohesive document is easier said than done. We’ve talked about steps for a successful IND before, but here are the most common errors we’ve seen made with IND submissions: 

VIEW THE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Clinical Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: